The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.
T. A. Yap
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
L. Yan
Employment or Leadership Position - Merck
Stock Ownership - Merck
A. Patnaik
Research Funding - Merck; Selumetinib
D. Olmos
No relevant relationships to disclose
I. Fearen
Employment or Leadership Position - Merck
Stock Ownership - Merck
R. D. Baird
No relevant relationships to disclose
K. P. Papadopoulos
Research Funding - Merck; Selumetinib
N. Tunariu
No relevant relationships to disclose
A. Biondo
No relevant relationships to disclose
H. Keilhack
Employment or Leadership Position - Merck
Stock Ownership - Merck
L. M. Delgado
Stock Ownership - Merck
A. Taylor
Employment or Leadership Position - Merck
Stock Ownership - Merck
S. C. Blackman
Stock Ownership - Merck
C. L. Carpenter
Employment or Leadership Position - Merck
Stock Ownership - Merck
S. Decordova
No relevant relationships to disclose
S. Heaton
No relevant relationships to disclose
M. D. Garrett
Research Funding - Merck
D. Sullivan
Research Funding - Merck
J. S. De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - AstraZeneca; Genentech; Merck
Honoraria - AstraZeneca; Genentech; Merck; Novartis
Research Funding - AstraZeneca
A. W. Tolcher
Consultant or Advisory Role - AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Adnexus (U); Ambit BioSciences (U); Amgen (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Bayer (U); BIND Biosciences (U); Biogen Idec (U); Chemokine (U); Curis (U); Dendreon (U); Dicerna (U); Endo Pharmaceuticals (U); Enzon (U); Exelixis (U); FivePrime (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); Insert Therapeutics (U); Intellikine (U); Johnson & Johnson (U); Merck (U); Micromet (U); Nektar (U); Novartis (U); Ortho Biotech (U); Otsuka (U); Pfizer (U); PPD Development (U); ProNAi (U); Regeneron (U); Sanofi (U); Santaris (U); Spectrum Pharmaceuticals (U); SuperGen (U); Symphogen (U); Vaccinex (U); Veeda Oncology (U)
Research Funding - Abbott Laboratories; Adnexus; Ambit BioSciences; Amgen; ArQule; Array BioPharma; Arresto; Astellas Pharma; AVEO; Azaya Therapeutics; Bayer; Biogen Idec; BiPar Sciences; Bristol-Myers Squibb; Calando; Centocor Ortho Biotech; Coronado Biosciences; Cougar Biotechnology; Curis; Cyclacel; Cylene; Daiichi Sankyo; Dendreon; Enzon; Exelixis; FivePrime; Genentech; Genta; GlaxoSmithKline; Hana BioSciences; Immunogen; Lilly; Merck; Merrimack; MethylGene; Millennium; Myrexis; Nektar; Nerviano; Novartis; OncoMed; Onyx; Ortho Biotech; Pfizer; PharmaMar; Proacta; ProNAi; Provia Biologics; Roche; Sanofi ; Schering-Plough; Schering-Plough; Spectrum Pharmaceuticals; SuperGen; Symphogen; Vaccinex